Amicus Therapeutics Inc. (NASDAQ:FOLD) SVP Daphne Quimi sold 8,546 shares of the stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $8.00, for a total value of $68,368.00. Following the sale, the senior vice president now owns 24,189 shares of the company’s stock, valued at approximately $193,512. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Amicus Therapeutics Inc. (NASDAQ:FOLD) opened at 9.20 on Monday. The firm’s market capitalization is $1.31 billion. Amicus Therapeutics Inc. has a one year low of $4.98 and a one year high of $11.78. The stock has a 50 day moving average price of $7.41 and a 200-day moving average price of $6.84.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The company earned $2.10 million during the quarter, compared to analyst estimates of $1.71 million. On average, equities analysts forecast that Amicus Therapeutics Inc. will post ($1.40) earnings per share for the current year.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

FOLD has been the subject of several recent analyst reports. Zacks Investment Research downgraded Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 18th. Chardan Capital set a $15.00 target price on Amicus Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 11th. Cowen and Company restated an “outperform” rating and set a $15.00 target price on shares of Amicus Therapeutics in a research note on Tuesday, November 8th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $17.00 price target on shares of Amicus Therapeutics in a report on Tuesday, November 8th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Amicus Therapeutics currently has an average rating of “Buy” and an average price target of $12.19.

Several hedge funds have recently added to or reduced their stakes in FOLD. BlackRock Fund Advisors increased its stake in Amicus Therapeutics by 1.6% in the first quarter. BlackRock Fund Advisors now owns 5,444,399 shares of the biopharmaceutical company’s stock worth $46,005,000 after buying an additional 83,654 shares in the last quarter. M&T Bank Corp bought a new stake in Amicus Therapeutics during the first quarter worth about $157,000. Candriam Luxembourg S.C.A. increased its stake in Amicus Therapeutics by 14.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 709,900 shares of the biopharmaceutical company’s stock worth $3,876,000 after buying an additional 90,000 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Amicus Therapeutics by 19.8% in the second quarter. Bank of New York Mellon Corp now owns 649,235 shares of the biopharmaceutical company’s stock worth $3,545,000 after buying an additional 107,215 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its stake in Amicus Therapeutics by 36.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 55,248 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 14,810 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

5 Day Chart for NASDAQ:FOLD

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.